To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored
trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these
trials until lack of patient benefit as assessed by investigator, or commercial availability
This study is being conducted to assess the long-term safety, tolerability, and efficacy of
sotatercept in PAH.
Through analysis of demographic factors (gender, age, smoking history and body mass index),
clinical indicators (signs and symptoms), sputum culture results (pseudomonas aeruginosa),
brain natriuretic peptide and imaging (scope and type of bronchiectasis), pulmonary function
index, inflammatory cytokines and inflammasome of patients, some factors will be found which
maybe be related to severity and prognosis of pulmonary hypertension associated with
The aim of this study was to try to reduce the required dose of etomidate used in anesthesia
for upper endoscopy and colonoscopy in critically ill cardiac patients who complain of severe
anemia in cardiac intensive care units by using a low dose of ketamine, which helps to reduce
the side effects of etomidate, the most important of which is its suppressive effect on the
adrenal gland and the secretion of cortisol in such critical cases, while maintaining
hemodynamic stability, and the patient's satisfaction.
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and
lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders. There
is limited evidence on psychological treatments for anxiety in PH; however, results support
the use of Cognitive Behavioural Therapy (CBT). Despite the prevalence and impact of anxiety
in PH; there are no widely available and/or disease specific pathways, thus highlighting an
unmet need in this population. This project aims to develop and pilot, using randomised
control trial methodology, a self-management intervention for individuals with PH based on
The main OBJECTIVE of this proposal is to extend the investigator's preclinical findings on
the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition
as a therapy for a devastating disease, pulmonary arterial hypertension (PAH).
There is strong evidence that BRD4 plays a key role in the pathological phenotype in PAH
accounting for disease progression and that BRD4 inhibition can reverse PAH in several animal
models. Intriguingly, coronary artery disease (CAD) and metabolic syndrome are more prevalent
in PAH compared with the global population, suggesting a link between these diseases.
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil
compared to placebo in improving exercise ability as measured by change from baseline in
6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with
Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the
disease progresses. According primarily to retrospective studies with up to 24 hours of
monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with
significant impact on survival.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24
hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.
What problems limit patients' response to exercise? Using exercise cardiac magnetic resonance
imaging to assess the heart's response, with simultaneous measurement of respiratory oxygen
and carbon dioxide levels to assess the lung and skeletal muscle responses, to identify the
rate-limiting factors affecting different types of patient
The study aim is to monitor, during exercise tests carried out in various conditions, the
alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would
be used as a surrogate for arterial PaCO2. Validity of this measurement needs to be assessed
against arterial sampling (either arterial, or arterialized capillary), especially with
regards to the lag time required by the CO2 diffusion from the arterial compartment (PaCO2)
to the cutaneous one (PtCO2), in particular when rapid changes of CO2 might be induced by
The evaluation will be done in 2 different settings:
- intensive care...